The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels
| Autor: | Iwona Flisiak, M Swiderska, Anna Baran |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty Systemic disease Administration Topical Adipokine 030209 endocrinology & metabolism Dermatology Severity of Illness Index Gastroenterology Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Psoriasis Area and Severity Index Psoriasis Internal medicine Severity of illness medicine Humans Prospective Studies Aged Aged 80 and over Metabolic Syndrome Retinol binding protein 4 biology business.industry Middle Aged medicine.disease Case-Control Studies Immunology biology.protein Female Dermatologic Agents Metabolic syndrome business Retinol-Binding Proteins Plasma Body mass index Biomarkers |
| Zdroj: | Journal of Dermatological Treatment. 27:114-119 |
| ISSN: | 1471-1753 0954-6634 |
| DOI: | 10.3109/09546634.2015.1079300 |
| Popis: | Psoriasis has been considered as chronic systemic disease. Retinol-binding protein-4 (RBP-4) might play a role in psoriasis and its comorbidities. The aim of this study was to investigate the associations between serum RBP-4 levels and disease severity, indicators of inflammation or metabolic syndrome and changes after topical treatment in psoriatic patients.Thirty-seven patients with relapse of plaque-type psoriasis and 16 healthy volunteers were examined. Blood samples were collected before and after 14 days of therapy. Serum RBP-4 concentrations were examined by enzyme-linked immunosorbent assay for correlation with psoriasis area and severity index (PASI), body mass index (BMI), inflammatory and biochemical markers and with efficacy of topical treatment.RBP-4 serum levels were increased in psoriatics compared to the controls, but without statistical significance (p = 0.2). No significant correlations between investigated adipokine and several indicators of metabolic disorders, nor BMI or PASI were found. A significant negative correlation with CRP was noted. After topical treatment serum RBP-4 level did not significantly change (p = 0.3), despite clinical improvement.RBP-4 might have a protective role in terms of chronic inflammation and comorbidities of psoriasis. The adipokine is presumably not useful in determining severity and the effectiveness of antipsoriatic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|